The investigation and management of myasthenia gravis (MG) has changed dramatically in the 50 years since Mary Walker first described the response to cholinesterase preparations.' The combination of sensitive radioimmunoassays for anti-acetylcholine receptor (AChR) antibodies2' and sophisticated electrophysiological techniques4 has allowed the diagnosis to be made at a much earlier stage in the evolution of the disease. The move away from high dose anticholinesterase therapy to thymectomy and immunosuppression has further improved the outlook for myasthenic patients,5 as have improvements in intensive care facilities and the use of plasmapheresis in the acute phase. 6 We have recently examined the effects of these developments on the management of MG over a nine year period in a sub-regional neurology centre which serves a population of approaching one million. Significant deficiencies were found in the sensitivity of the AChR antibody assay in our region. The The anti-acetylcholine receptor antibody assay was performed in the regional immunology laboratory (PBW) using a method modified from that described by Brenner et al.'
Acetylcholine receptors were isolated from human calf muscle obtained from amputations. Homogenised muscle was extracted with Triton X-100 and the preparation ultracentrifuged. The resulting supernatant was aspirated and stored at 4°C with 0-1% azide added as a preservative. Alpha-bungarotoxin (10 pg, Sigma T3019) was radio-labelled with 25 mBq 1251 (Amersham) and the resulting preparation separated from free iodine by addition of a cationic ion exchange resin (Amberlite IRA 400). Two hundred and fifty mic1es of it reepter tptIon was labefle4 4y the hd4tion of 25 A1 ,*habungatocoxin oquivalent to 25-50 000 cpm.
One hundred microlitres of patient's diluted
Deficiencies in anti-acetylcholine receptor antibody measurement in myasthenia gravis (1:10) serum were added to the receptor-bungarotoxin complex and incubated overnight at room temperature. The resulting complexes were separated from the free label by addition of a suspension of 1-2 mg of staphylococcal dried cells (Sigma S0504). After two hours, the tubes were centrifuged and washed twice to remove unbound radio-labelled receptor. The lower limit of detection for the assay was determined by measuring the radioactive counts bound in normal individuals, from which the upper limit of the normal range was calculated by taking the mean plus three standard deviations. AChR antibody levels obtained at the time of diagnosis were used throughout the study to exclude the effects of treatment on antibody production.
Results
Of a total of 86 patients, only 60 were examined for the presence of the anti-acetylcholine receptor antibody. These comprised 18 cases (30%) of pure ocular myasthenia (type I), 38 cases (63%) with generalised disease (type II), 3 (5%) with acute fulminating disease (type III) and 1 (2%) with late fulminating disease (type IV).
Patients were included in the series on clinical criteria alone. However, support for the diagnosis ofmyasthenia was gained from investigations in a large proportion of patients ( No trend was found in anti-AChR antibody titre in relation to disease classification (table 2; ANOVA F3,27 = 1-89, p > 0.05).
Discussion
As a retrospective case note study, this work is limited by the lack of comprehensive investigation in some cases. There was also a high percentage of cases of ocular myasthenia (31 % across the group of 86 patients) compared with other series with a frequency of between 9-29%.7 l" Similarly, only 6% had fulminating disease (types III and IV) compared with I  II  III  IV   0  17  10  7  0  0  1  8  3  5  0  0  2  9  3  6  0  0  3  2  0  2 The use of staphylococcal protein A rather than anti-human IgG antisera may account in part for the low sensitivity of our assay, but it is probable that other methodological reasons are involved. One possibility relates-to the receptor preparation which in these studies was isolated from single individuals rather than using preparations of pooled material. Samples from this same group of patients are currently being re-analysed taking these factors into account.
The findings of this study emphasise the value of medical audit, even when applied to apparently well established practices. Similar studies into the sensitivity of the anti-AChR antibody assay should be performed in other centres and, if comparable results are found, consideration should be given to creating a central reference laboratory for this assay. 
